GM-CSF plays a key role in zymosan-stimulated human dendritic cells for activation of Th1 and Th17 cells

Cytokine

Volumn 55, Issue 1, 2011, Pages 79-89

  Wei, Wen Chi ^a,b   Su, Yi Hsuan ^a,c   Chen, Swey Shen ^d,e   Sheu, Jyh Horng ^b   Yang, Ning Sun ^a,c,f  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d IgE Therapeutics Inc   (United States)

^e ILTAB   (United States)

^f NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

Dendritic cell; Granulocyte macrophage colony stimulating factor; Th1; Th17; Zymosan

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 27; LIPOPOLYSACCHARIDE; ZYMOSAN;

ARTICLE; CELL MATURATION; CELL POLARITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL SHAPE; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOCYTE ACTIVATION; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TH1 CELLS; TH17 CELLS; ZYMOSAN;

EID: 79956343073     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.03.017     Document Type: Article

References (50)

1. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
2. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
3. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
4. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997, 90:3245-3287.
5. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
6. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
7. Owaki T., Asakawa M., Fukai F., Mizuguchi J., Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol 2006, 177:7579-7587.
8. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
9. Burgess A.W., Camakaris J., Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem 1977, 252:1998-2003.
10. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999, 50:507-529.
11. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
12. Rini B.I., Small E.J. The potential for prostate cancer immunotherapy. Crit Rev Oncol Hematol 2003, 46(Suppl.):S117-125.
13. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007, 18:226-232.
14. Shi Y., Liu C.H., Roberts A.I., Das J., Xu G., Ren G., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006, 16:126-133.
15. Esen N., Kielian T. Effects of low dose GM-CSF on microglial inflammatory profiles to diverse pathogen-associated molecular patterns (PAMPs). J Neuroinflammation 2007, 4:10.
16. Eksioglu E.A., Mahmood S.S., Chang M., Reddy V. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol 2007, 35:1163-1171.
17. Sonderegger I., Iezzi G., Maier R., Schmitz N., Kurrer M., Kopf M. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 2008, 205:2281-2294.
18. Zekovic D.B., Kwiatkowski S., Vrvic M.M., Jakovljevic D., Moran C.A. Natural and modified (1→3)-beta-d-glucans in health promotion and disease alleviation. Crit Rev Biotechnol 2005, 25:205-230.
19. Food and Drug Administration. Specification 194 and FDA Appendix A Food Additives; 1983. SEC 201(s) of the FD&C Act.
20. Food and Drug Administration. Food Additives permitted for direct addition to food for human consumption: Curdlan 21 CFR 172. Federal Reg 1996;61:65941.
21. Pillemer L., Ecker E.E. Anticomplementary factor in fresh yeast. J Biol Chem 1941, 137:139-142.
22. Young S.H., Ye J., Frazer D.G., Shi X., Castranova V. Molecular mechanism of tumor necrosis factor-alpha production in 1→3-beta-glucan (zymosan)-activated macrophages. J Biol Chem 2001, 276:20781-20787.
23. Au B.T., Williams T.J., Collins P.D. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-activating factor as an autocrine modulator. J Immunol 1994, 152:5411-5419.
24. Duan X., Ackerly M., Vivier E., Anderson P. Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function. Cell Immunol 1994, 157:393-402.
25. de la Rosa G., Yanez-Mo M., Samaneigo R., Serrano-Gomez D., Martinez-Munoz L., Fernandez-Ruiz E., et al. Regulated recruitment of DC-SIGN to cell-cell contact regions during zymosan-induced human dendritic cell aggregation. J Leukoc Biol 2005, 77:699-709.
26. Edwards A.D., Manickasingham S.P., Sporri R., Diebold S.S., Schulz O., Sher A., et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 2002, 169:3652-3660.
27. Ara Y., Saito T., Takagi T., Hagiwara E., Miyagi Y., Sugiyama M., et al. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology 2001, 103:98-105.
28. Gantner B.N., Simmons R.M., Canavera S.J., Akira S., Underhill D.M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003, 197:1107-1117.
29. Goodridge H.S., Simmons R.M., Underhill D.M. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol 2007, 178:3107-3115.
30. Dillon S., Agrawal S., Banerjee K., Letterio J., Denning T.L., Oswald-Richter K., et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 2006, 116:916-928.
31. Gerosa F., Baldani-Guerra B., Lyakh L.A., Batoni G., Esin S., Winkler-Pickett R.T., et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008, 205:1447-1461.
32. Morisaki T., Matsumoto K., Onishi H., Kuroki H., Baba E., Tasaki A., et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 2003, 16:175-182.
33. Song S.Y., Kim H.S. Strategies to improve dendritic cell-based immunotherapy against cancer. Yonsei Med J 2004, 45(Suppl):48-52.
34. Hasebe H., Nagayama H., Sato K., Enomoto M., Takeda Y., Takahashi T.A., et al. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother 2000, 54:291-298.
35. Whiteside T.L., Stanson J., Shurin M.R., Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004, 173:1526-1534.
36. Wang C.Y., Chiao M.T., Yen P.J., Huang W.C., Hou C.C., Chien S.C., et al. Modulatory effects of Echinacea purpurea extracts on human dendritic cells: a cell- and gene-based study. Genomics 2006, 88:801-808.
37. Traidl-Hoffmann C., Mariani V., Hochrein H., Karg K., Wagner H., Ring J., et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005, 201:627-636.
38. Underhill D.M. Macrophage recognition of zymosan particles. J Endotoxin Res 2003, 9:176-180.
39. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003, 3:984-993.
40. Tracey K.J., Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994, 45:491-503.
41. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
42. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
43. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
44. Corinti S., Albanesi C., la Sala A., Pastore S., Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001, 166:4312-4318.
45. Hamilton J.A. GM-CSF in inflammation and autoimmunity. Trends Immunol 2002, 23:403-408.
46. Cook A.D., Braine E.L., Hamilton J.A. Stimulus-dependent requirement for granulocyte-macrophage colony-stimulating factor in inflammation. J Immunol 2004, 173:4643-4651.
47. Brown G.D., Herre J., Williams D.L., Willment J.A., Marshall A.S., Gordon S. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003, 197:1119-1124.
48. Simmons S.J., Tjoa B.A., Rogers M., Elgamal A., Kenny G.M., Ragde H., et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999, 39:291-297.
49. Chang E.Y., Chen C.H., Ji H., Wang T.L., Hung K., Lee B.P., et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000, 86:725-730.
50. Stix G. Overcoming self. Sci Am 2004, 291:40-41.